Technology Bundle ID
TAB-3493

Methods and Compositions for the Inhibition of PIN1 for the Treatment of Immune, Proliferative and Neurodegenerative Disorders

Applications
Linked ID
E-203-2012-0
Lead Inventors
Kun Ping Lu (Beth Israel Deaconess Medical Center)
Co-Inventors
Anton Simeonov (NCATS)
Matthew Boxer (NCATS)
Min Shen (NCATS)
Mindy Davis (NCATS)
Rajan Pragani (NCATS)
Shuo Wei (Beth Israel Deaconess Medical Center)
Xiao Zhen Zhou (Beth Israel Deaconess Medical Center)
ICs
This technology includes the compositions and methods for inhibiting PIN1 for the treatment of disorders characterized by elevated PIN1 levels (e.g., immune disorders, proliferative disorders, and neurodegenerative disorders) with small molecules. Pin1 dysregulation has been associated with a number of pathological conditions. In particular, PIN1 has been shown to promote oncogenesis by modulating several oncogenic signaling pathways and its overexpression has been shown to correlate with poor clinical outcome. There are no current drug-like small molecule inhibitors of PIN1 that could be used therapeutically.
Commercial Applications
Inhibitors of PIN1 could be used to treat diseases such as: immune disorders, proliferative disorders, and neurodegenerative disorders.
Competitive Advantages
There are currently no drug-like small molecule inhibitors of PIN1.

Request More Info

Licensing Contact: